China cancer biomarkers market is growing at a CAGR of around 11.8% during the forecast period. China has a strong market for cancer biomarkers due to huge government investments in R&D and Life Science projects, prevalence of cancer and increasing adoption of personalized medicine. All these factors are contributing to the growth of China cancer biomarker market. Biomarker- targeted therapies approval in China is led by the development of various oncology biomarkers, such as EGFR, RAS, HER2, BRCA. There efficacy in the diagnosis of treatment of cancer has led the researchers and biopharmaceuticals to focus personalized medicine on biomarkers for cancer. In addition, the Government of China is investing heavily in life science research spurring the development and adoption of biomarkers for personalized medicine. The 13th Five-year Plan (2015-2020) by the Chinese government will further fuel the growth of the market as the plan focusses on the development of innovative medicines, with biomedicine being identified as a key priority.

Visit for Global Cancer Biomarker Market Report at: https://www.omrglobal.com/industry-reports/cancer-biomarkers-market

In October 2017, a US based company called Gentris, working in the field of genomic biomarkers in clinical studies, signed a Memorandum of Understanding to form a biomarker collaboration with the Shanghai Institutes of Preventative Medicine. This partnership is done with the objective to discover new biomarkers. It will result in the development of translational research and epidemiological projects based on pharmacogenomics. In addition, it will provide clinical sample banking, which are services provided by the Gentris to the clients in the US for clinical trials and genomic biomarker programs. This is augmenting the growth of the china cancer biomarker market.

In 2015, there were nearly 4.3 million new cancer patients in China including 730,000 cases of lung cancer, which accounted for 36% of the total cases.  Early diagnosis and risk assessment are essential for Lung cancer diagnosis. Many factors involved in those processes could serve as biomarkers for early diagnosis or early screening tools for lung cancer which has augmented the growth of lung cancer.  In January 2018, China’s FDA approved Amoy Diagnostics' SuperARMS EGFR mutation analysis test as a companion diagnostic for EGFR TKI-based non-small cell lung cancer drugs.

Research Methodology

The market study of the China cancer biomarker market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for biotechnology companies, research laboratories, pharmaceutical companies, research institutions, hospitals, and other related companies for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. China Cancer Biomarker Market Research and Analysis by Biomarker Type

2. China Cancer Biomarker Market Research and Analysis by Cancer Type

3. China Cancer Biomarker Market Research and Analysis by Application

4. China Cancer Biomarker Market Research and Analysis by Ownership

The Report Covers

• Comprehensive research methodology of the China Cancer biomarker market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the China Cancer biomarker market.
• Insights about market determinants which are stimulating the China Cancer biomarker market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.